Xilio Therapeutics, Inc. (XLO)
After hours:
- GlobeNewswire
Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2024 Financial Results
Expect to initiate Phase 2 trial for XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4, in combination with atezolizumab in patients with microsatellite stable colorectal cancer (MSS CRC) in the third quarter of 2024 Plan to report clinical data for XTX101 and XTX301, a tumor-activated IL-12, in the fourth quarter of 2024 Advancing research-stage pipeline of tumor-activated bispecifics and immune cell engagers Anticipate cash runway into the second quarter of 2025 WALTHAM, Mass., May 14, 2024 (
- Zacks
Xilio's (XLO) Shares Surge 79.8% in a Month: Here's Why
Xilio (XLO) rallies 79.8% in a month on an exclusive global licensing agreement with Gilead Sciences to develop XTX301 for advanced solid tumors.
- GlobeNewswire
Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2023 Financial Results
On track with plans to initiate Phase 2 trial for XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4, in combination with atezolizumab in patients with microsatellite stable colorectal cancer (MSS CRC) in the third quarter of 2024 Granted Gilead exclusive license to develop and commercialize XTX301, a tumor-activated IL-12 Anticipates cash runway into the second quarter of 2025 WALTHAM, Mass., April 01, 2024 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnolo
